Capricor Therapeutics (CAPR) Net Margin (2011 - 2024)
Capricor Therapeutics (CAPR) posted quarterly Net Margin of 56.9% for Q4 2024, down 5225.0% year-over-year from 1.11% in Q1 2024, and up 99.02% quarter-over-quarter from 5794.83% in Q3 2024.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Net Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' Net Margin history runs 13 years deep, the most recent figure standing at 56.9% for Q4 2024.
- In Q4 2024, Net Margin fell 5225.0% year-over-year to 56.9%; the TTM figure through Sep 2025 stood at 1614.0% (down 92197.0% YoY), while the FY2024 annual figure was 181.71%, down 3697.0% from the prior year.
- Net Margin for Q4 2024 stood at 56.9%, up from 5794.83% in the prior quarter.
- The five-year high for Net Margin was 4.65% in Q4 2023, with the low at 71092.46% in Q3 2020.
- The 5-year median for Net Margin is 1009.21% (2022), against an average of 7877.83%.
- The sharpest annual moves came in 2020 and 2021: Net Margin slumped 6988160 bps in 2020, then surged 1879918 bps in 2021.
- Capricor Therapeutics' Net Margin stood at 7229.02% in 2020, then surged by 66 bps to 2482.54% in 2021, then jumped by 66 bps to 849.84% in 2022, then surged by 99 bps to 4.65% in 2023, then tumbled by 1125 bps to 56.9% in 2024.
- Business Quant data shows CAPR's Net Margin at 56.9% in Q4 2024, 5794.83% in Q3 2024, and 582.84% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -62.81% |
| Sep 30, 2024 | -555.20% |
| Jun 30, 2024 | -295.71% |
| Mar 31, 2024 | -101.94% |
| Dec 31, 2023 | -6.86% |
| Sep 30, 2023 | -103.22% |
| Jun 30, 2023 | -195.60% |
| Mar 31, 2023 | -274.38% |
| Dec 31, 2022 | -800.77% |
| Sep 30, 2022 | -400.30% |
| Jun 30, 2021 | -2,482.54% |
| Mar 31, 2021 | -12,622.31% |
| Dec 31, 2020 | -7,224.51% |
| Sep 30, 2020 | -23,187.59% |
| Jun 30, 2020 | -6,987.31% |
| Mar 31, 2020 | -1,134.53% |
| Dec 31, 2019 | -661.60% |
| Sep 30, 2019 | -1,130.84% |
| Jun 30, 2019 | -498.04% |
| Mar 31, 2019 | -1,114.76% |